Zonisamide is considered a broad spectrum:
A. Antibiotic
B. Anticonvulsant
C. Antiviral
D. NSAID
E. Antihistamine.
Zonisamide is a sulfonamide-based anticonvulsant that is approved for use as adjunctive therapy in adults with partial seizures.
Zonisamide may be an inhibitor of carbonic anhydrase, although it is not one of the main mechanisms of action.
Zonisamide can act by blocking the repeated activation of voltage-gated sodium channels, resulting in a reduction of T-type calcium channel currents, or by allosterically binding to GABA receptors.
This latter action can inhibit the absorption of GABA, an inhibitory neurotransmitter, while increasing the uptake of excitatory neurotransmitter glutamate.
Zonisamide (ZD) is a last-generation anti-epileptic indicated in combination in the treatment of partial epilepsy with or without secondary generalization in adults and children (> 6 years).
ZD is extensively metabolized in the liver so its activity may be affected by the concomitant use of enzyme inducing drugs or inhibitors.
It can be the cause of drowsiness, anorexia or rash. Renal lithiases are possible (due to a mechanism of action identical to that of topiramate) and require sufficient hydration.
A. Antibiotic
B. Anticonvulsant
C. Antiviral
D. NSAID
E. Antihistamine.
Zonisamide is a sulfonamide-based anticonvulsant that is approved for use as adjunctive therapy in adults with partial seizures.
Zonisamide may be an inhibitor of carbonic anhydrase, although it is not one of the main mechanisms of action.
Zonisamide can act by blocking the repeated activation of voltage-gated sodium channels, resulting in a reduction of T-type calcium channel currents, or by allosterically binding to GABA receptors.
This latter action can inhibit the absorption of GABA, an inhibitory neurotransmitter, while increasing the uptake of excitatory neurotransmitter glutamate.
Zonisamide (ZD) is a last-generation anti-epileptic indicated in combination in the treatment of partial epilepsy with or without secondary generalization in adults and children (> 6 years).
ZD is extensively metabolized in the liver so its activity may be affected by the concomitant use of enzyme inducing drugs or inhibitors.
It can be the cause of drowsiness, anorexia or rash. Renal lithiases are possible (due to a mechanism of action identical to that of topiramate) and require sufficient hydration.
Labels
Pharma